How this company measures up on the fundamentals that matter
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
Trading characteristics and market positioning
Balance sheet strength and cash generation — the foundation of long-term value
SEC Form 4 filings — what company insiders are buying and selling
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-26 | LOXAM TERI | Chief Financial Officer | 75,000 | — | |
| 2026-03-26 | NATH KABIR | Chief Executive Officer | 175,000 | — | |
| 2025-03-11 | LOXAM TERI | Chief Financial Officer | 25,000 | — | |
| 2024-10-24 | GOLDSMITH GEORGE JAY | Beneficial Owner of more than 10% of a Class of Security | 776,565 | $4,993,313 | |
| 2024-10-24 | MALIEVSKAIA EKATERINA | Beneficial Owner of more than 10% of a Class of Security | 1,553,130 | $9,986,626 | |
| 2024-09-26 | ATAI LIFE SCIENCES NV | Beneficial Owner of more than 10% of a Class of Security | 2,660,000 | $16,093,000 |
Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15